Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent

Janssen Alleges Compound And UC Patents Infringed By ABP 654 Biosimilar

01 Dec 2022

• By Dean Rudge

Amgen targets ustekinumab among the next wave • Source: Alamy/Marlon Trottmann

More from Biosimilars

More from Products